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Concise summaries
• The major value of the barium study in pa-
tients with reflux symptoms is its ability to strat-
ify them into various risk groups for Barrett’s
esophagus (BE) to determine the relative need
for endoscopy and biopsy.
• Recent advances in multidetector computed
tomography (MDCT), now allow routine vi-
sualization of the entire esophagus in a
single breath-hold. Positron emission tomog-
raphy/computed tomography (PET/CT) is not
sufficiently sensitive and specific enough to dif-
ferentiate BE from other benign disorders, but
with technical improvements, may help detect
malignant transformation and even dysplasia in
patients with this disorder.
• It is striking that although retrospective studies
tend to confirm an association with increas-
ing length of the BE segment, this has not, in
general, been borne out in prospective studies.
Excess body fat does raise one’s risk of compli-
cated gastroesophageal reflux disease (GERD),
including BE, and centralized fat is the pre-
dominant risk factor. However, whether this
is true for both men and women equally re-
mains unclear. Specific effects of central obe-
sity, independent of body mass index (BMI),
on reflux mechanisms potentially include ele-
vated intragastric pressure and a disruption of
the esophago-gastric junction (EGJ) integrity,
but data are still scarce. There is substantial rea-
son to suspect that circulating adipokines may
promote BE.
• Alterations in levels of circulating factors related
to obesity, including adipokines directly secret-
ed from adipose tissue, are likely involved in the
development of BE and neoplastic progression.
Visceral fat is metabolically active, and has been
strongly associated with low serum levels of po-
tentially protective (e.g., adiponectin), or pro-
inflammatory cytokines (e.g., interleukin-1 ,
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interleukin-6, and tumor necrosis factor-),
which may play a role in the development of BE.
• However, although the prevalences of erosive
esophagitis and BE are both associated with
BMI, there are no compelling data to suggest
that healing rates are affected by BMI.
• Surgical treatment of obesity has positive effect
on GERD and its complications, e.g., BE.
1. Do particular clinical factors influence
the development and extent of BE?
Eamonn M. M. Quigley
e.quigley@ucc.ie
BE presents a formidable challenge to the clinician
and endoscopist: on the one hand, its predilection
to progress to adenocarcinoma of the esophagus has
been widely publicized, whereas on the other, there
is no doubt that, amidst a worldwide epidemic of
GERD, BE has become very frequent. If, as indicated
by a recent community survey from Sweden, for ex-
ample, BE may be found among 2% of the general
population, many of whom are asymptomatic, we
have a very considerable challenge indeed, as only
a very tiny minority of such individuals will ever
progress to adenocarcinoma. It is self-evident that
population screening for BE is not going to be a
cost effective approach;1 what we need is a strategy
that will permit the identification, at an appropri-
ately early stage, of that subgroup who are at risk
for progression. Can clinical features assist in either
predicting the presence of BE or, more importantly,
its risk for progression to cancer?
At endoscopy, BE is almost always identified in
the context of chronic reflux disease and a hiatal her-
nia; it must be remembered that these individuals
have been selected on the basis of chronic and often
troublesome symptoms, a factor that has tended to
bias the outcome of many studies in this area. The
findings of the study by Chak and colleagues tend to
confirm these clinical impressions: in comparison
to GERD patients without BE, patients with BE (or
adenocarcinoma of the esophagus or EGJ), were
more likely to be male, older, obese, smokers, and
drinkers of alcohol. It must be conceded that many
of these associations were modest. BE subjects also
tended to have more frequent and severe heartburn
but no significant relationship between BE and
duration of symptoms was evident. The strongest
predictor of BE or related cancers (odds ratio 6.4)
was, however, a family history of BE, or adenocar-
cinoma of the esophagus or EGJ.2 Relationships
between symptomatic GERD and BE have been the
subject of a recent meta-analysis,3 which dissects
the interaction between GERD and BE further.
Although confirming a relationship between GERD
symptoms and long-segment BE, they found no
association with short-segment BE. This is more
bad news; if short-segment BE is an important en-
tity with a predilection to progression, looking for
GERD symptoms will not be helpful in identifying
it.
The lack of sufficient numbers did not permit
Chak and colleagues to differentiate between those
with BE alone and those who had progressed to
cancer.2 To address this all important issue, Prasad
and colleagues have recently performed a compre-
hensive systematic review of predictors for progres-
sion in BE and their results are not very encour-
aging.4 Yes—age, male gender, and length of BE
segment were linked to progression to adenocarci-
noma but the association was weak. Although obe-
sity was identified as an independent risk factor for
the development of adenocarcinoma of the esopha-
gus, in Lagergren and his colleagues’ study based on
the Swedish national data base,5 there was not, as
yet, in the judgment of Prasad and colleagues, com-
pelling evidence to link obesity with BE progres-
sion. As in their examination of many other clinical
and demographic factors (age, tobacco and alcohol
use, acid suppression), Prasad and colleagues found
the data limited, fraught with methodological is-
sues (small sample sizes, study design, method, and
extent of follow-up) and often conflicting with re-
gard to both the direction and magnitude of the ef-
fect. Among endoscopic features, BE segment length
does confer some, albeit inconsistent, relationship
with progression. It is striking that although retro-
spective studies tend to confirm an association with
increasing length of the BE segment, this has not, in
general, been borne out in prospective studies.
Although we may think that we can identify clini-
cal features that indicate whether a given individual
may harbor BE, these very same features do not ap-
pear to be very helpful in helping us to make the
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much more important prediction: who is at risk for
progression through dysplasia to adenocarcinoma.
Recent meta-analyses, while revealing hints of what
may be relevant, have also identified the important
short-comings of existing data and should encour-
age all involved in this area to collaborate in large
prospective studies of the natural history of this
common condition; only then will be able to truly
identify those clinical features that can help us to
select patients for endoscopic surveillance with the
expectation that we will truly impact on mortality
from adenocarcinoma of the esophagus.
2. What is the respective influence of BMI




It has been well established that an elevated BMI
is associated with symptomatic GERD, erosive
esophagitis, BE, and esophageal adenocarcinoma.
Recently, investigators have begun to ask whether
the actual distribution of body fat is more impor-
tant than just having an excess amount. For example,
it appears that central adiposity (also called “vis-
ceral adiposity”) is important for the development
of BE.6 Such central body fat could be causing more
severe GERD simply through mechanical factors,
such as a greater gastroesophageal pressure gradi-
ent.7 It also appears that central obesity may elicit
more frequent transient lower esophageal sphincter
relaxations.8 Finally, excess centralized fat is associ-
ated with a greater likelihood of a hiatal hernia. All of
these factors play a role in the pathogenesis of GERD.
However, investigators have also begun to won-
der about the role of adipocytokines, peptides pro-
duced by adipose tissue that have several effects
on cell growth, apoptosis, and other potentially
neoplastic factors. It is interesting to note that
adipocytokines, such as adiponectin and leptin, are
produced predominantly by visceral fat, the very fat
that seems associated with BE. Men tend to have
greater amounts of visceral fat than women, a fact
that correlates nicely with the observation that men
are twice as likely as women to develop BE and six
or seven times as likely to progress to esophageal
adenocarcinoma compared to women.
Investigators have noted an association between
serum leptin and BE in men, with greater levels cor-
relating with higher risk for BE.9 Interestingly, an
inverse association was noted between serum lep-
tin and BE in women, arguing that there may be
gender differences in how body fat imparts risk for
BE. It is possible that central fat plays a dominant
role in the genesis of BE in men, but that other
BMI-associated factors predominate in women. For
example, peripheral fat (nonvisceral fat) is the pre-
dominant source of estrogens in postmenopausal
women, and estrogens are associated with a greater
risk of symptomatic GERD.10
In summary, it appears that excess body fat does
raise one’s risk of complicated GERD, including BE,
and that centralized fat is the predominant risk fac-
tor. However, whether this is true for both men and
women equally remains unclear.
3. Can it be said that central obesity may




The continuous rise of the prevalence of both obesity
and GERD in Western societies over the last three
decades suggests a link between these conditions.
The aim of this article is to provide a short overview
of literature investigating the effects of central obe-
sity on esophageal acid exposure and mechanisms
potentially increasing reflux and thus leading to BE.
A significantly higher prevalence of reflux related
symptoms in overweight and obese subjects was
found in 7 of 9 cross-sectional surveys included in a
meta-analysis of papers based on validated or struc-
tured questionnaires.11 Pooled data from these stud-
ies showed an adjusted odds ratio (OR) for reflux
symptoms of 1.43 (95% CI 1.16–1.77) in subjects
with a BMI of 25–29.9 and 1.94 (95% CI 1.47–
2.57) in individuals with a BMI ≥ 30. Jacobson et
al. found an almost linear increase in the OR for
frequent reflux symptoms with body mass BMI in
women participating in the Nurses’ Health Study.12
(Table 1).
An increase of esophageal acid exposure in over-
weight and obese patients has been described for
subjects with and without symptoms suggestive of
GERD. In most comparative studies, patients were
stratified by BMI. Data on a specific role of cen-
tral obesity are scarce. In a study of 206 patients
undergoing 24-hour esophageal pH-monitoring by
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Table 1. Adjusted ORs (95% confidence interval) based on data of 2,306 women reporting heartburn and/or acid
regurgitation at least once a week and 3,904 asymptomatic women, adjusted for age, smoking status, total activity,
daily caloric intake, intake of alcohol, coffee, tea, and chocolate, use of postmenopausal hormone therapy, use of
antihypertensive or asthma medication, and presence or absence of diabetes mellitus11
OR 0.67 1.0 1.38 2.2 2.43 2.92 2.93
(95% CI) (0.48–0.93) (1.13–1.67) (1.81–2.66) (1.96–3.01) (2.35–3.62) (2.24–3.85)
BMI <20.0 20.0–22.4 22.5–24.9 25.0–27.4 27.5–29.9 30.0–34.9 ≥35.0
El-Serag et al., waist circumference (WC) and BMI
were positively correlated with parameters of acid
reflux.13 As an example, for each unit increase of
BMI, 2.76 more reflux episodes in the postprandial
period were encountered (P < 0.001).
A 1 cm increase of WC was associated with 0.85
more reflux episodes (P = 0.002). In a multivari-
able linear regression model including both BMI
(as categorical variable) and WC (as continous vari-
able) a BMI ≥ 30 was no longer associated with any
parameter of acid exposure.
Potential mechanisms of how central obesity
worsens acid reflux include a temporary or perma-
nent disruption of the EGJ integrity and elevated
intragastric pressure, resulting in an elevated gastro-
esophageal pressure gradient. In a high-resolution
manometry study of 285 patients Pandolfino et al.
found a significant correlation of BMI and WC
with intragastric pressure (inspiration, BMI (r =
0.57), WC (r = 0.62) P < 0.0001; expiration, BMI
(r = 0.58), WC (r = 0.64), P < 0.0001).7 Further-
more a weaker, but still significant correlation of the
separation of lower esophageal sphincter and crural
diaphragm with BMI (r = 0.17, P < 0.005) and WC
(r = 0.21, P < 0.001) could be demonstrated.
In a case control study of 197 patients newly di-
agnosed with specialized intestinal metaplasia and
418 GERD controls, a high waist to hip ratio (male
≥ 0.9, female ≥ 0.8) increased the risk for visible BE
(adjusted OR 1.9, 95% CI 1.0–3.5) and long segment
BE (adjusted OR 4.1, 95% CI 1.5–11.4) independent
of BMI.14
In summary, it can be said that obesity is associ-
ated with a higher prevalence of reflux symptoms,
increased esophageal acid exposure, and prevalence
of BE. Specific effects of central obesity, independent
of BMI, on reflux mechanisms potentially include
elevated intragastric pressure and a disruption of
the EGJ junction integrity, but data are still scarce.
The association of anthropometric data with BE re-
quires further study as well, as this has important
implications for screening.
4. What is the impact of proinflammatory
adipocytokines and metabolic syndrome
on the development of Barrett’s mucosa?
Joel H. Rubenstein
jhr@umich.edu
There is substantial reason to suspect that circulat-
ing adipokines may promote BE. In brief, obesity is
associated with both BE and esophageal adenocar-
cinoma. Although this is likely partly explained by a
mechanical effect promoting GERD, and by dietary
habits that promote GERD, obesity is also associ-
ated with a number of other cancers for which no
known mechanical mechanism exists. It is increas-
ingly recognized that adipose tissue is not an inert
storage compartment, but rather metabolically ac-
tive, secreting a number of substances. It is believed
that those other cancers are promoted by adipokines
secreted from adipose tissue, or other circulating
factors. Adipokines secreted from visceral adipose
appear to be particularly involved in inflammation.
For instance, visceral adipocytes secrete TNF-, and
50–75% of circulating IL-6 in obese subjects may be
secreted from omental adipocytes.15,16 Inflamma-
tion is believed to be intrinsic to the development
of BE.
The rapid rise in incidence of esophageal ade-
nocarcinoma might be explained by synergies in
the multiple mechanisms by which obesity might
promote this cancer (mechanical plus humoral).
The potential roles for adipokines and other cir-
culating factors in the development of BE and
esophageal adenocarcinoma are just beginning to
be explored. Here, I summarize the currently avail-
able data for some of the leading factors under
consideration.
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Diabetes and insulin resistance
Increased visceral fat is associated with insulin
resistance. Insulin resistance is associated with a
chronic inflammatory state,17 and elevated insulin
levels stimulate cell growth and inhibit apoptosis.4
Hyperinsulinemia has been associated with the
development of cancers of the colon, pancreas,
and endometrium.18 In a case-control study utiliz-
ing national Veterans Health Administration data,
we found no evidence for an association between
diabetes mellitus with a combined outcome of ade-
nocarcinoma of the lower esophagus or gastric car-
dia.19 However, we were not able to examine the
effects on the risk of adenocarcinoma of the esoph-
agus separately from the risk of gastric cardia in that
study. Since then, diabetes was associated specifically
with EAC in a population-based study.20 However,
the effect of diabetes appeared to be partially atten-
uated by GERD symptoms, tobacco use, and BMI.
Given the body of evidence supporting a role of in-
sulin resistance in other epithelial cancers, further
research on its role in BE is warranted.
Adiponectin
Adiponectin is a peptide secreted primarily by vis-
ceral adipocytes. Circulating levels are paradoxi-
cally inversely related to obesity, and are lower in
men than women. Low levels have been associated
with increased risk of cancers of the stomach, colon,
prostate, breast, and uterus.21 Receptors specific for
adiponectin are found in the esophageal mucosa,
and adiponectin can induce apoptosis and inhibit
proliferation in cell lines of esophageal adenocarci-
noma.22,23 In a pilot study, we found a trend toward
lower blood levels of adiponectin in patients with BE
compared to patients undergoing upper endoscopy
for other indications.24
However, in a separate, larger study, we found
no such association with total adiponectin levels.25
Adiponectin circulates in various multimers, each
with specific actions. The low molecular weight
(LMW) form appears to be antiinflammatory, and
the high molecular weight form is proinflamma-
tory. We found that a high ratio of LMW to total
adiponectin was strongly inversely associated with
the presence of BE, compared to GERD controls,
including after adjustment for abdominal obesity.25
The specific roles of the molecular weight isoforms
of adiponectin in the development of BE deserve
further study.
Leptin
Leptin is a peptide secreted by primarily by
adipocytes; it acts to signal satiety to the brain. Most
obese humans are resistant to this signal, and have
elevated circulating leptin levels. In addition to its
effects on satiety, leptin stimulates proliferation and
inhibits apoptosis in cell lines of esophageal ade-
nocarcinoma.26 Blood levels have been correlated
with an increased risk of colorectal cancer.27 Ele-
vated leptin has also been directly associated with
the presence of BE among men, including after ad-
justment for GERD and obesity.9 However, an in-
verse association with BE was found in women. The
reason for these discordant findings is unclear. In a
smaller study composed mostly of men, no associ-
ation was found between plasma leptin and BE.28
BE was associated with elevated gastric fundus lev-
els of leptin, controlling for BMI, compared to pa-
tients with esophagitis or to patients undergoing
upper endoscopy for other indications. Therefore,
intralumenal leptin, rather than circulating leptin,
may be more important for its effect on esophageal
mucosa.
Ghrelin
Ghrelin is a peptide secreted by the gastric fundus.
It signals to the brain to stimulate appetite. Most
obese humans have suppressed circulating levels of
ghrelin—that is, they continue to eat despite low
levels. In a cell line of esophageal adenocarcinoma,
ghrelin inhibited COX-2 and IL-1 expression in-
duced by TNF-.22A small study found that very ele-
vated levels of circulating ghrelin (>3.2 ng/mL) were
protective against the development of esophageal
adenocarcinoma, but only among overweight sub-
jects.29 The investigators noted a threshold effect,
with no effect at lower concentrations.
Insulin-like growth factor axis
In addition to its insulin-like effects via the in-
sulin receptor, insulin-like growth factor one (IGF-
1) stimulates proliferation and inhibits apoptosis
in many tissues via the IGF-1 receptor, including
in esophageal epithelium and intestinal crypts.30–33
Insulin enhances the synthesis of IGF-1, and hy-
perinsulinemia and obesity are associated with in-
creased levels of free IGF-118,34 Most circulating
IGF-1 is bound to IGF binding protein-3 (IGFBP-
3), and bound IGF-1 is inactive.35 IGFBP-3 in-
hibits cell growth and is proapoptotic.36 IGF func-
tions primarily in paracrine and autocrine manners,
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making it difficult to study epidemiologically. How-
ever, polymorphisms of the genes encoding IGFs
and the IGF receptors have been associated the risk
of BE and esophageal adenocarcinoma.37–39 Ele-
vated circulating IGF-1 levels have been associated
with esophageal adenocarcinoma.40
Conclusions
Alterations in levels of circulating factors related
to obesity, including adipokines directly secreted
from adipose tissue, are likely involved in the
development of BE and neoplastic progression. Re-
search in this field is relatively new, and many ques-
tions remain unanswered.
5. May body fat distribution in men, where
visceral obesity is more common, be an




There are gender-related differences in the dis-
tribution of GERD and its potential complica-
tions including BE. GERD symptoms seem to be
equally prevalent between men and women; erosive
esophagitis is more common among men,41 BE is
much more common in men (70–80%),42 whereas
esophageal adenocarcinoma is dominated by men43
(Fig. 1).
Differences in obesity do not explain gender dif-
ferences. Abdominal obesity explains some of the
Figure 1. GERD symptoms seem to be equally prevalent be-
tween men and women, whereas erosive esophagitis is more
common in men,41 BE is much more common in men (70–
80%),42 and esophageal adenocarcinoma is dominated by men.
epidemiological features of BE and esophageal ade-
nocarcinoma. The distribution of body fat tends to
be more visceral than truncal in high-risk groups for
BO including Caucasians (compared with African
Americans), and men (compared with women).44
Two recent case-control studies have shown abdom-
inal diameter measured as WC to be a risk factor of
BE independent of BMI, whereas the association
between BMI and BE disappeared after adjustment
of abdominal diameter.6,45 These studies indicate
that abdominal fat is possibly the key factor linking
obesity and BE.
Only one study reported the association between
WC and the risk of BE in men and women sepa-
rately. Edelstein et al. in a case-control study (193
BE cases and 211 non-BE controls) conducted in
the United States reported higher risk estimates
for large WC and BE in men with an odds ra-
tio of 5.9 (95% confidence intervals 1.8–19.4) than
in women with an odds ratio of 2.9 (95% confi-
dence intervals 8–11.0).6 The other three studies
that examined the association between obesity and
BE risk did not convey useful information on the
differences between men and women. One study
was conducted exclusively in men,46 the second had
no abdominal obesity measurements,47 and third
matched case and controls on gender.45
The leading hypothesis is that abdominal obe-
sity promotes gastroesophageal reflux through in-
creased pressure stress and anatomical disruption
of the gastroesophageal junction.
Obese individuals may experience extrinsic gas-
tric compression by surrounding adipose tissue
leading to increase intragastric pressures and subse-
quent relaxation of the lower esophageal sphincter,
thus facilitating abnormal reflux (Fig. 2). A study
of 285 patients7 analyzed the relationship between
obesity, pressure stresses on the OGJ, and the mor-
phology of the OGJ pressure segment itself using a
solid-state manometric assembly with 36 circumfer-
ential sensors spaced at 1 cm intervals. Intragastric
pressure, as well as gastroesophageal pressure gradi-
ent, during both expiration and inspiration was sig-
nificantly higher in obese and overweight patients
compared with those with a normal BMI. WC was
an independent risk factor for increased intragastric
pressure, whereas BMI was no longer significantly
associated with pressure independent of waist. The
associations were stronger in men than women.
These changes lead to increased reflux across
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Figure 2. The relationship between obesity, pressure stresses on the OGJ, and reflux disease.
the lower esophageal sphincter with subsequent
increased esophageal exposure to gastroduodenal
contents. We conducted a cross-sectional study
of 206 consecutive patients undergoing 24-hour
pH-metry who were not on acid-suppressing
medications.13 Both BMI > 30 and high WC were
associated with a significant increase in acid reflux
episodes, long reflux episodes (>5 min), time with
pH < 4, as well as a calculated summary score. The
association between obesity and esophageal acid
exposure also became attenuated when adjusted
for WC suggesting that the latter may mediate a
large part of the effect of obesity. Finally, visceral
fat is metabolically active, and has been strongly
associated with low serum levels of potentially
protective (e.g., adiponectin), or proinflammatory
cytokines (e.g., interleukin-1, interleukin-6, and
tumor necrosis factor-), which may play a role in
the development of BE.
6. Does BMI induce a difference in healing




The short answer is “no.” We generally do not mon-
itor the natural healing rate of erosive esophagi-
tis, and this has certainly not been correlated with
BMI. Healing rates have been monitored in the set-
ting of clinical trials evaluating the efficacy of acid-
mediating agents. However, these studies were never
primarily designed to specifically look for an asso-
ciation between BMI and healing rates. Another,
perhaps more fruitful, way to think about this ques-
tion is to ask whether BMI is associated with the
efficacy of acid-mediating agents. For example, one
can think about whether excess body fat can affect
the pharmacokinetics of these drugs. However, de-
spite theoretical reasons why BMI might have some
association with the distribution or metabolism
of acid-mediating agents, there is no published
evidence suggesting any important differences in
the pharmacokinetics of acid-mediating agents and
BMI?48
Despite this, have there been well-established
clinical differences observed in patient response
rates to proton pump inhibitors (PPIs) or histamine
type 2 receptor antagonists (H2RAs) based upon
BMI? Again, the answer is no. For example, in
one pooled analysis with a total of 2,458 subjects
from three randomized controlled trials of PPIs in
nonerosive reflux disease, BMI was not predictive for
patient response.49 Further, no clear association was
seen in post hoc analyses of PPI studies in both ero-
sive and nonerosive reflux disease specifically asking
if response rates differed by BMI.50–51
Therefore, although the prevalences of erosive
esophagitis and BE are both associated with BMI,52
there are no compelling data to suggest that healing
rates are affected by BMI.
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7. Is it likely that intraabdominal fat is a
risk marker of GERD, BE, and
adenocarcinoma? What are the means by
which obesity may (also) promote
carcinogenesis in BE patients?
Michele Cicala, Silvia Cocca, and
Michele Pier Luca Guarino
m.cicala@unicampus.it
Obesity has increased considerably in the last few
decades, with a prevalence from 15% in 1976–1980
to 32% in 2003–2004 in the United States and in
several parts of Europe and Asia. The health impli-
cations of obesity are relevant, affecting almost ev-
ery apparatus. Obesity and GERD, as well as GERD
complications, such as BE and adenocarcinoma, are
clearly related.45,53
The finding that increased abdominal fat, rather
than a high BMI value, is strongly associated with
GERD and BE has been well established. In a
hospital-based study, the increase in visceral, rather
than subcutaneous, fat, assessed at computerized
tomography (CT) scan, has been shown to be
an independent and strong risk factor for BE.53
Furthermore, data from a case control study in
which patients with an incidental diagnosis of BE
were compared both with controls and patients
with GERD, have provided further support to the
hypothesis that abdominal obesity, in terms of ab-
dominal circumference, is a risk factor of BE and is
associated with severe GERD symptoms.2 Another
measure of abdominal girth, the waist to hip ratio,
more than the BMI, seems to be strongly associated,
irrespective of symptom severity, with the presence
of BE and, in particular, with long-segment Barrett’s
metaplasia.6
A positive association between increased abdom-
inal diameter and the risk of esophageal adenocarci-
noma, but not cardia or squamous cell carcinoma,
has recently been demonstrated by Kubo et al.54
These findings might explain the higher risk of BE
and adenocarcinoma in white men, who are more
commonly affected by abdominal obesity.
A potential limitation of all case-control studies is
the difficulty in establishing a temporal association
between exposure and outcome, for instance be-
tween the onset and duration of obesity and the end-
point, the disease. Moreover, observational studies
are subject to several other confounding factors, and
the effect of weight loss on the development of the
disease has not yet been established.
In summary, given all these limitations, intraab-
dominal fat could likely be considered a risk marker
of GERD, BE and adenocarcinoma; however, further
research is mandatory to obtain direct evidence of
this pathway.
Another important question concerns the means
by which obesity may also promote carcinogenesis
in BE patients. It is known that metabolic effects
of obesity, particularly abdominal obesity, may also
contribute to carcinogenesis. Fat, located in the vis-
ceral compartment, induces changes in hormone
production such as adiponectin and leptin, insulin
and IGFs, and in cytokine production, all of which
are able to affect cellular proliferation and apop-
tosis.55 Several studies, have demonstrated that in-
creased serum levels of leptin, a cytokine discovered
in 1994 as a regulator of body weight and energy
balance, are directly correlated with onset of var-
ious tumors and with an increased risk of BE.55
On the other hand, levels of adiponectin, that are
usually inversely associated with the risk of malig-
nancies related to obesity, are found to be lower in
obese patients than in normal weight patients.55 As
a result of this impaired metabolic activity the in-
creased production of fatty acids, leading to insulin
resistance and result in hyperinsulinemia, may have
a direct effect upon insulin receptors as well as an
effect mediated by decreasing IGF binding proteins,
thus increasing IGF bioavailability, both of which
result in reduced apoptosis and increased cell pro-
liferation. Finally, abdominal obesity could also play
a role in the development of BE by increasing intra-
gastric pressure and, therefore, promoting reflux.
Surprisingly, evidence confirming this pathway is
still weak.53
Further investigations on the endocrine effects of
adipose tissue and its potential role in carcinogenesis
are now mandatory.
8. Does surgery for obesity result in
better control of GERD and risk of
malignancy in BE?
Reza A. Hejazi and Richard W. McCallum
richard.mccallum@ttuhsc.edu
The prevalence of GERD is markedly higher
in overweight and obese individuals as com-
pared to those with normal BMI,56 since GERD
itself is now recognized as an obesity-related
comorbidity.
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Figure 3. Adjustable laparoscopic gastric banding; Vertical banding gastroplasty; Roux en Y gastric bypass. Adapted from De
Groot et al.58 and with permission from John Wiley and Sons.
Bariatric surgery actually has become a widely
accepted form of treatment for severe obesity,
and several studies have demonstrated a signifi-
cant reduction in GERD symptoms and medication
utilization, as well as weight and metabolic comor-
bidity, including diabetes, hypertension and dyslipi-
demia.57 The different techniques for performing
bariatric surgery have variable effects on GERD and
subsequently on the risk of BE. Roux en Y gastric
bypass (Fig. 3), as the most performed bariatric op-
eration in the United States, was found in majority
of studies to have a positive effect on GERD symp-
toms.3 Vertical banding gastroplasty as a restric-
tive procedure, on the other hand, has no change
or even, based on some reports, may cause an in-
crease of GERD.58 Although laparoscopic adjustable
gastric banding might have a beneficial effect, the
results of this procedure are still conflicting.3 Pre-
operative selection of GERD patients, as well as em-
ploying the most beneficial procedure, are the goals.
The good news here is that the resolution of Barrett’s
disease and atypia of the esophageal epithelial after
gastric bypass and laparoscopic gastric bypass/LAP-
BAND were reported in just two cases.59 After la-
paroscopic placement of adjustable gastric banding,
Barrett’s esophagus could be a rare (one case) but
not unexpected complication, and the incidence of
it is still unknown.60
Conclusions
GERD is common problem in obese and overweight
populations. Surgical treatment of obesity has pos-
itive effect on GERD and its complications, such as
BE.
Roux en Y gastric bypass has the most favor-
able impact on GERD symptoms, although cer-
tain restrictive procedures such as laparoscopic gas-
tric bypass/LAP-BAND have also been reported to
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have some postive effects on Barrett’s disease and
esophageal dysplasia.
9. What is the role of double-contrast
esophagography in the diagnosis and




The classic radiologic features of BE consist of a
mid-esophageal stricture or ulcer, often associated
with a sliding hiatal hernia and GER.61 These stric-
tures typically appear as ring-like constrictions or
as tapered areas of narrowing below the level of the
aortic arch. However, strictures are actually more
common in the distal esophagus in patients with
BE, so most cases do not fit the classic description
of a high stricture or ulcer.62 A reticular mucosal
pattern has also been described as a relatively spe-
cific sign of BE on double-contrast esophagograms,
particularly if located just distal to a midesophageal
stricture.62 However, a reticular mucosal pattern is
present on barium studies in only 5–30% of all pa-
tients with BE.
Other morphologic findings of reflux disease,
such as hiatal hernias, GER, reflux esophagitis, and
peptic strictures, can be detected on double-contrast
studies in the vast majority of patients with BE,
but these findings frequently occur in patients with
uncomplicated reflux disease.63 Thus, those radio-
graphic findings that are relatively specific for BE are
not sensitive, and those findings that are more sen-
sitive are not specific. As a result, double-contrast
esophagography has traditionally been thought to
have limited value for diagnosing BE.
Gilchrist et al. introduced a novel approach for
the diagnosis of BE on double-contrast esophagog-
raphy by stratifying patients based on specific ra-
diologic criteria.64 Patients who were classified at
high risk for BE because of a high stricture or ul-
cer or a reticular mucosal pattern were almost al-
ways found to have this condition, so endoscopy
and biopsy should be performed in this group for
a definitive diagnosis. A larger group of patients
were classified at moderate risk for BE because of
esophagitis or strictures in the distal esophagus;
16% of these patients were found to have BE, so
the decision for endoscopy in this group should be
based on the severity of symptoms, age, and overall
health of the patients (i.e., whether they are rea-
sonable candidates for surveillance). However, the
majority of patients were classified as low risk for
BE because of the absence of esophagitis or stric-
tures in the esophagus; many of these patients were
found to have mild reflux esophagitis, but less than
1% had BE, so these patients can be treated empir-
ically for their reflux symptoms without need for
endoscopy. Thus, the major value of the barium
study in patients with reflux symptoms is its abil-
ity to stratify them into these various risk groups for
BE to determine the relative need for endoscopy and
biopsy.64,65
10. Cross-sectional imaging in the
detection of BE
Richard M. Gore, Kiran H. Thakrar, Geraldine M.
Newmark, Uday K. Mehta, and Jonathan W. Berlin
rgore@uchicago.edu
Upper gastrointestinal endoscopy and barium
esophagography are the primary means of evalu-
ating patients with known or suspected esophageal
pathology.65,66 Although these examinations su-
perbly depict the esophageal mucosa, they are
limited by their inability to directly image the
esophageal wall and surrounding adventitia, fat, and
lymph nodes. Recent advances in MDCT now allow
routine visualization of the entire esophagus in a sin-
gle breath-hold with thin collimation and isotropic
voxels. This allows the production of high-quality
multiplanar reformations and 3D reconstruction
images. The sensitivity of MDCT in the evaluation
of esophageal disease is further enhanced by proper
distention of the esophagus by the oral administra-
tion of effervescent granules and water and opti-
mally timed administration of intravenous contrast
material.
Although detection of the actual metaplas-
tic columnar epithelium of BE is beneath the
spatial resolution of MDCT, there are a num-
ber of secondary features that help suggest
diagnosis, especially of long segment, circumferen-
tial disease.
MDCT is superb in the identification of hiatal
hernias (Fig. 4). There is extension of a portion of
the proximal stomach or other abdominal contents
into the lower mediastinum. An abnormally wide
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Figure 4. MDCT scan in a patient subsequently proven to have Barrett’s esophagus. (A) Coronal and (B) sagittal reformatted
images demonstrate a hiatal hernia and Schatzki’s ring (yellow arrows). Note the gastroesophageal reflux (red arrow).
esophageal hiatus with increased separation of the
esophagus and diaphragmatic crura is often present.
MDCT can also document the presence of gas-
troesophageal reflux (see Fig. 4) however this is
less reliably detected than by conventional barium
esophagrams and nuclear medicine reflux studies.
Oral contrast material is routinely given for abdom-
inal and pelvic CT scans and this contrast mate-
rial may be visualized in the distal esophagus and
can show the presence of a stricture or Schatzki’s
ring.
MDCT is superb in depicting mural thickening
(Fig. 5) of the esophagus and the diagnosis can be
confidently made in patients with a well-distended
esophagus. Mural thickening of the esophagus as
shown on MDCT is nonspecific and can be seen in a
variety of benign and malignant disorders including:
reflux esophagitis, infectious esophagitis, tubercu-
losis, radiation esophagitis, eosinophilic esophagi-
tis, BE, Crohn’s disease of the esophagus, achalasia,
scleroderma, diffuse esophageal spasm, esophageal
pseudodiverticulosis, adenocarcinoma of the esoph-
agus, squamous cell carcinoma of the esopha-
gus, lymphoma of the esophagus, and esophageal
metastases.67
Five mm is a useful threshold for esophageal
wall thickening in patients with esophagitis. Indeed,
some 55% of all patients with esophagitis have an
esophageal wall thickness of 5 mm or greater on
MDCT. Benign or malignant tumors of the esopha-
gus are usually manifested on CT by focal, asymmet-
ric thickening of the esophageal wall, whereas mural
thickening in esophagitis is concentric and circum-
ferential, and usually involves a relatively long seg-
ment of the esophagus.67
Some 20% of patients with esophagitis may also
demonstrate mural stratification, in which the axi-
ally imaged esophagus has a target appearance. This
is caused by the combination of mucosal enhance-
ment and a hypodense submucosa. In the small
bowel and colon, the target sign almost always in-
dicates benign disease associated with submucosal
edema resulting from inflammation, infection, or
ischemia.
Other clues to esophageal pathology include the
distribution of intraluminal air on MDCT. Intralu-
minal air is normal in the esophagus, but distention
of more than 10 mm at a fixed point, such as the
carina, is uncommon. Any segment over 20 mm
should be considered abnormal. The normal lower
esophageal sphincter should be closed. In the up-
per 30% of the esophagus (to about the top of the
aortic arch) and from 61% to 75% of the length of
the esophagus (behind the base of the heart) less
than 5% of the lumina are larger than 10 mm in
diameter.68
The greatest luminal dimensions and variation
occur in the area between where the diaphragm
first appears and where the esophagus enters the
abdomen. Here, 15 mm should the upper limits
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Figure 5. MDCT scan in a patient with reflux esophagitis and
a long segment of Barrett’s esophagus proven by endoscopic
biopsy. (A) Axial, (B) coronal reformatted, and (C) sagittal re-
formatted images show a large hiatal hernia (yellow arrows) as-
sociated with a long segment of mural thickening of the esoph-
agus (red arrow). (A) Submucosal edema produces the target
appearance of the axially imaged esophagus.
of normal. An air–fluid level on any section of the
esophagus is abnormal.68
In summary, the following constellation of find-
ings should raise the possibility of BE or at least
esophagitis on MDCT: hiatal hernia, mural thicken-
ing of the esophagus in a symmetric, circumferential
manner, the target sign, too much intraluminal air,
air-fluid levels, foodstuffs or tablets in the esopha-
gus. These CT findings should be carefully searched
for on pulmonary embolism and thoracic aortic dis-
section MDCT scans performed on patients with
chest discomfort. A minority number of these pa-
tients will ultimately be shown to have significant
esophageal pathology.
11. Can PET/CT differentiate BE from other
benign esophageal disorders?
Richard M. Gore, Kiran H. Thakrar, Geraldine M.
Newmark, Uday K. Mehta, and Jonathan W. Berlin
rgore@uchicago.edu
Combined PET/CT with fluorine18 fluoro-
deoxyglucose (FDG) is a hybrid device that fuses
structural information provided by multidetec-
tor CT with the functional imaging provided by
PET (Fig. 6). This technique improves the radio-
logic assessment of normal anatomic structures and
pathological lesions. Cellular FDG uptake is pre-
dominantly related to expression of the protein glu-
cose transport 1. This protein is ubiquitously ex-
pressed in almost all cell types, but its over ex-
pression in dysplastic and malignant tissue is quite
frequent and leads to intracellular accumulation
of FDG, which is visualized on PET. The high le-
sion to background contrast and whole body data
acquisition on FDG PET represent critical advan-
tages over CT and MRI, where contrast between
pathologic and normal structures may be limited.
FDG PET has been developed to quantitatively as-
sess local glucose metabolism. PET can help differ-
entiate benign and malignant tumors, determine
the degree of malignancy, evaluate the effective-
ness of chemotherapy and/or radiotherapy, and help
predict prognosis. Indeed FDG PET has been used
to screen for malignancies.69
FDG PET is a well-accepted method for the de-
tection and staging of a number of malignancies
including lung, breast, colorectal, and esophageal
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Figure 6. PET/CT of Barrett’s esophagus. (A) Axial, (B) coronal, and (C) sagittal images of the esophagus show mural thickening
of the esophagus on the CT (white arrow), increased metabolic activity on PET (red arrow), mural thickening of the esophagus and
increased metabolic activity on the PET/CT (yellow arrow), and increased metabolic activity on coronal scanogram (black arrow)
components of the examination.
cancer. The applications of FDG PET in the clinical
diagnosis of BE have not been established.
Preliminary experimental work has demon-
strated the efficacy of high-resolution PET scan-
ning to examine the degree and time depen-
dency of changes in FDG uptake in rat esophageal
tissues during the esophageal reflux injury car-
cinogenic progression pathway. FDG accumula-
tion is significantly elevated in esophageal tis-
sues three and six month (correlating to BE with
high grade dysplasia and early adenocarcinoma)
than that at one week and one month (reflux
esophagitis), and this accumulation corresponds
to the histopathologically observed progression of
squamous epithelium to hyperplasia to metapla-
sia and onto adenocarcinoma. This early work
suggests that FDG PET scanning may play an im-
portant role in the assessment of a subset of pa-
tients that are at risk for the esophagitis to meta-
plasia to dysplasia to esophagitis-adenocarcinoma
sequence.70
Nonspecific esophageal uptake is a common find-
ing when interpreting PET/CT studies and is usu-
ally due to reflux esophagitis. This is not surprising
considering that about 15% of the population
suffers from reflux disease. These benign lesions,
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Figure 6. Continued
however, can resemble early esophageal malignan-
cies. The clinical challenge is that, on the one hand,
the only chance for cure of esophageal carcinoma
is its early detection, and, on the other hand, the
rate of false positives among nonspecific esophageal
uptake is too high to recommend further eval-
uation with endoscopy in all of those cases.
Therefore, the differentiation between early ma-
lignant and benign lesions has important clinical
implications.71,72
The differential diagnosis of increased FDG
uptake on PET CT includes: reflux esophagitis,
infectious esophagitis, radiation esophagitis, BE,
primary and secondary achalasia, scleroderma, dif-
fuse esophageal spasm, intramural pseudodivertic-
ulosis, tuberculosis, Crohn’s disease, adenocarci-
noma, squamous cell carcinoma, lymphoma, and
metastases.
When evaluating abnormal PET CT findings of
the esophagus, Roedl et al.73 have suggested closely
interrogating the scans for the following features:
esophageal thickness, focality and location of the
lesion, eccentricity of the esophageal thickening,
and degree of metabolic activity-standard uptake
value. Roedl et al. found no significant differences
in esophageal thickness on CT and location of the
lesion between the 36 early malignant and the 66
benign lesions. However, higher SUV, greater le-
sion focality, and greater eccentricity of the mu-
ral thickening are significantly increased in the
early malignant group when compared with benign
lesions.73
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Figure 6. Continued
At the present time, PET CT is not sufficiently sen-
sitive and specific enough to differentiate BE from
other benign disorders but, with technical improve-
ments, may help detect malignant transformation
and even dysplasia in patients with this disorder.
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